Natera to buy Foresight Diagnostics in $450 million oncology tech deal
AUSTIN – Natera Inc has acquired Foresight Diagnostics, a move that expands its portfolio of tests that detect trace amounts of cancer left after treatment, in a deal worth up to $450 million. The all-stock transaction includes a $275 million upfront payment and up to $175 million in earnouts tied to future revenue and reimbursement…